Essex Investment Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Essex Investment Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-63,661	Closed	-$1.17M	–	347
2016 Q4	$1.17M	Sell	63,661 -58,005	-48%	-$1.13M	0.19%	137
2016 Q3	$2.31M	Buy	121,666 +16,427	+16%	+$298K	0.37%	64
2016 Q2	$1.7M	Buy	105,239 +73,922	+236%	+$1.04M	0.28%	93
2016 Q1	$376K	Hold	31,317	–	–	0.06%	262
2015 Q4	$446K	Sell	31,317 -7,700	-20%	-$102K	0.07%	246
2015 Q3	$456K	Buy	+39,017	New	+$585K	0.07%	238

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Essex Investment Management's AMPH Position: Q1 2017 in Review

Essex Investment Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2017, closing a stake of 63,661 shares — an estimated $1.17M sold.

Essex Investment Management first reported a position in AMPH in Q3 2015 and held it in 6 quarters. The position peaked at $2.31M in Q3 2016. 116 funds tracked by Wall St. Rank hold AMPH as of Q1 2017.

Essex Investment Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Essex Investment Management sold 63,661 Amphastar Pharmaceuticals shares in Q1 2017, an estimated $1.17M.
Essex Investment Management first reported a position in Amphastar Pharmaceuticals in Q3 2015 and held it in 6 quarters.
Essex Investment Management's Amphastar Pharmaceuticals position peaked at $2.31M in Q3 2016.
116 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2017.

Based on Essex Investment Management's 13F filing for Q1 2017, filed 27 Apr 2017.